Canagliflozin and Longevity: The SGLT2 Inhibitor Rewriting Lifespan Science

When the Interventions Testing Program (ITP), the most rigorous independent lifespan-testing consortium in biogerontology, publishes results showing a drug extends median lifespan in mice, the field pays attention. When that drug extends lifespan in both sexes, and does so more robustly than most compounds ever tested, the field stops and takes note. Canagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor originally approved for type 2 diabetes, did exactly that. It extended median male lifespan by 14% and female lifespan by 7% in genetically heterogeneous mice, findings that place it among a very short list of pharmacological agents with credible, reproducible longevity evidence in mammals [1]. For researchers, clinicians, and patients thinking seriously about healthspan, those numbers demand a coherent explanation.

The explanation, it turns out, is not a single mechanism. Canagliflozin sits at an unusual intersection of metabolic reprogramming, mitochondrial biology, cardiovascular protection, and cellular stress signaling. Understanding why this particular molecule, from a drug class developed to lower blood sugar, might be the most pharmacologically compelling longevity tool currently available requires tracing each of those threads back to their molecular origins. The story begins, predictably, in the kidney, and ends somewhere considerably more profound.

From Diabetic Kidneys to the Longevity Conversation

SGLT2 inhibitors were designed with a specific and humble purpose: block the transporter in the kidney's proximal tubule that recaptures glucose from the filtered urine, forcing the body to excrete roughly 60 to 80 grams of glucose per day in the urine rather than returning it to circulation. The result is a reliable drop in blood glucose without stimulating insulin secretion, a pharmacological profile that initially seemed useful but unremarkable. No one designing canagliflozin in the early 2000s was thinking about sirtuins or mTOR or mitochondrial uncoupling. The longevity story emerged from clinical trials designed to prove cardiovascular safety, and it arrived as a surprise.

The CANVAS trial, which enrolled over 10,000 patients with type 2 diabetes and high cardiovascular risk, showed that canagliflozin reduced major adverse cardiovascular events, heart failure hospitalizations, and renal progression to a degree that could not be explained by glucose lowering alone [2]. This "off-target" cardiovascular protection prompted investigators to ask a more fundamental question: was canagliflozin doing something to cellular biology beyond glucose excretion? The ITP's decision to test it in healthy, non-diabetic mice was a direct consequence of that question. The 14% extension in male median lifespan, confirmed across multiple sites, suggested the answer was yes [1].

Canagliflozin extended median male lifespan by 14% in the ITP's genetically heterogeneous mouse model, a magnitude comparable to rapamycin and placing it among the most reproduced pharmacological longevity findings in mammalian biology.

For context, the ITP has tested dozens of compounds over nearly two decades. Most fail. Rapamycin, the mTOR inhibitor and the most celebrated pharmacological longevity intervention in mouse biology, extended median lifespan by 9 to 14% in that same model depending on sex and study conditions [3]. Canagliflozin's male lifespan extension is at the upper end of that range, and its effects appear to operate through largely distinct biological pathways. Understanding those pathways is where the science becomes genuinely fascinating.

Caloric Restriction Without the Calorie Restriction: The Metabolic Reframing

One of the most durable findings in longevity biology is that reducing caloric intake, without malnutrition, extends lifespan across species from yeast to rodents [4]. The mechanisms involve reduced insulin and IGF-1 signaling, activation of AMPK (the cell's energy-sensing master switch), and suppression of mTOR, the nutrient-sensing complex that accelerates cellular aging when chronically activated. The problem, clinically, is that meaningful caloric restriction is extraordinarily difficult to sustain, and its translation to humans remains uncertain. What canagliflozin may offer is something that mimics key downstream features of caloric restriction without requiring patients to eat less.

By continuously excreting glucose into the urine, canagliflozin creates a state of relative substrate limitation. The body perceives a persistent, mild caloric deficit even when caloric intake is unchanged. This is not a trivial effect. The liver responds by increasing fatty acid oxidation and producing ketone bodies, principally beta-hydroxybutyrate, as alternative fuel. Circulating ketone levels rise modestly but consistently in patients taking SGLT2 inhibitors, even in the absence of diabetes or dietary carbohydrate restriction [5]. This mild, sustained nutritional ketosis has downstream consequences for cellular signaling that are now well-characterized.

Beta-hydroxybutyrate is not merely fuel. It is a signaling molecule. At physiologically relevant concentrations, it inhibits class I and II histone deacetylases (HDACs), enzymes that suppress the transcription of genes involved in oxidative stress resistance and longevity pathways [6]. It also activates HCAR2, a G-protein coupled receptor on immune cells that reduces the NLRP3 inflammasome, the molecular assembly line responsible for producing the inflammatory cytokines that drive the chronic, low-grade inflammation now known as inflammaging [7]. In this sense, canagliflozin's ketogenic effect functions like a metabolic dimmer switch, turning down inflammatory tone across multiple tissues simultaneously.

The AMPK activation component adds another layer. When cellular glucose availability drops, AMPK is phosphorylated and activated, and it proceeds to orchestrate a metabolic shift toward catabolism, conservation, and repair. It phosphorylates and inhibits mTORC1, the complex that, when chronically active, suppresses autophagy and accelerates cellular senescence. It activates the transcription factor FOXO3a, which upregulates antioxidant enzymes and DNA repair pathways associated with exceptional human longevity [8]. AMPK activation is, in effect, the cell telling itself to enter maintenance mode rather than growth mode, a shift that most longevity interventions, from fasting to metformin to rapamycin, converge upon through different entry points.

The Mitochondrial Dimension: Uncoupling, Efficiency, and the Aging Cell

Beyond its metabolic signaling effects, canagliflozin has a direct and somewhat unexpected relationship with mitochondria that may be central to its longevity biology. Mitochondria are often described as the cell's power plants, but a more precise analogy is that they are electrochemical engines: they burn fuel to generate a proton gradient across the inner mitochondrial membrane, and that gradient drives the synthesis of ATP. The efficiency with which this process runs, and the degree to which protons leak across the membrane without producing ATP, a phenomenon called mitochondrial uncoupling, has profound implications for both energy metabolism and the production of reactive oxygen species (ROS).

Canagliflozin has been shown to inhibit Complex I of the mitochondrial electron transport chain at pharmacologically relevant concentrations [9]. This effect, which it shares mechanistically with metformin, reduces electron flow through the chain, lowering the membrane potential and consequently reducing the "electron leak" that generates superoxide, the primary mitochondrial free radical. The result is less oxidative damage per unit of ATP produced, a fundamentally different relationship between metabolic activity and cellular aging. Think of it as tuning an engine to run cleaner rather than simply running it less.

Canagliflozin's partial inhibition of mitochondrial Complex I reduces the electron leak that generates superoxide, producing less oxidative damage per unit of cellular energy generated, a cleaner metabolic signature associated with longevity across species.

There is a secondary mitochondrial effect worth examining closely. In cardiac and renal cells, canagliflozin has been shown to promote mitophagy, the selective autophagy of damaged or dysfunctional mitochondria [10]. Mitophagy is essential to mitochondrial quality control: it is the cellular equivalent of identifying and scrapping defective machinery before it poisons the factory floor. Aging cells accumulate dysfunctional mitochondria, partly because mitophagy slows with age and partly because oxidative damage accelerates mitochondrial deterioration. A drug that simultaneously reduces oxidative damage at the source and increases clearance of damaged mitochondria addresses the problem from two directions. The Mitophagy Formula supplements this pathway through nutritional cofactors, but canagliflozin's pharmacological promotion of mitophagy represents a more upstream intervention with broader systemic reach.

These mitochondrial effects are not isolated to one tissue. Canagliflozin's ability to cross cell membranes and its distribution across organ systems means its metabolic and mitochondrial effects manifest in the heart, kidney, liver, brain, and skeletal muscle simultaneously. This systemic quality is part of what distinguishes it from interventions that target a single organ or pathway.

Cardiovascular and Renal Protection: Where the Clinical Evidence Is Strongest

The cardiovascular outcomes data for canagliflozin represent some of the most consistent findings in modern clinical pharmacology. In CANVAS, canagliflozin reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 14% compared to placebo [2]. The reduction in heart failure hospitalization was even more striking, approximately 33%, and has been replicated across the SGLT2 inhibitor class, suggesting a class effect mediated by mechanisms beyond glucose control. The CREDENCE trial, which focused specifically on patients with diabetic kidney disease, showed a 30% reduction in the composite kidney outcome and was stopped early due to overwhelming efficacy [11].

The mechanism behind the heart failure benefit is now fairly well understood and connects directly to the longevity biology described above. The failing heart increasingly relies on glucose as its primary fuel, which is metabolically inefficient. Canagliflozin's shift toward fatty acid and ketone oxidation provides the failing myocardium with more energetically dense substrates. Additionally, the osmotic diuresis induced by glucosuria reduces preload and afterload on the heart, a hemodynamic benefit comparable to loop diuretics but without the electrolyte disturbances. The combination of metabolic and hemodynamic benefits is, from a cardiovascular biology perspective, unusually comprehensive.

For the kidneys, the glomerular hemodynamic effects are equally important. In diabetes and hypertension, the afferent arteriole supplying the glomerulus dilates while the efferent arteriole constricts, creating hyperfiltration, a state of excessive pressure within the delicate glomerular filtration units that accelerates structural damage over years and decades. Canagliflozin restores normal glomerular pressure through a tubuloglomerular feedback mechanism: the increased sodium delivery to the macula densa caused by SGLT2 blockade triggers afferent arteriolar constriction, reducing intraglomerular pressure and protecting against the slow-motion kidney injury that characterizes metabolic disease [12]. This mechanism operates independently of blood glucose and is why the renal protective effects extend to non-diabetic populations.

These cardiovascular and renal benefits matter profoundly for longevity. Cardiovascular disease and chronic kidney disease are among the leading drivers of both morbidity and premature mortality in developed populations, and their roots lie in decades of metabolic dysregulation. A drug that addresses their underlying hemodynamic and metabolic drivers, rather than simply managing symptoms downstream, is acting at a point in the causal chain that determines biological age, not just disease presence. To monitor the relevant cardiovascular markers while taking canagliflozin, the Heart Vitality Panel provides the lipid and inflammatory data needed to contextualize treatment response over time.

The Senolytic Adjacent Effect: Cellular Senescence and Inflammaging

Cellular senescence, the state in which cells permanently exit the cell cycle but resist apoptosis, accumulating in tissues and secreting a cocktail of inflammatory cytokines and matrix-degrading enzymes known as the senescence-associated secretory phenotype (SASP), is one of the hallmarks of aging with the most direct clinical relevance. Senescent cells are not merely passengers in the aging process; they actively accelerate it. Their SASP components promote chronic low-grade inflammation, impair tissue repair, and create a microenvironment that pushes neighboring healthy cells toward senescence in a cascade that compounds with age.

Canagliflozin does not directly clear senescent cells the way senolytics like dasatinib or quercetin are proposed to. What it does is suppress several of the downstream signals that make senescent cells so damaging. The NLRP3 inflammasome inhibition mediated by beta-hydroxybutyrate directly reduces the production of IL-1beta and IL-18, two of the most potent SASP cytokines [7]. AMPK activation suppresses NF-kB, the transcription factor that acts as the master regulator of inflammatory gene expression and is chronically activated in both senescent cells and the tissues that surround them [13]. The net effect is a measurable reduction in systemic inflammatory markers, including C-reactive protein, IL-6, and TNF-alpha, that has been documented in multiple clinical populations.

This anti-inflammatory biology connects directly to the organs most vulnerable to inflammaging: the brain, the vasculature, and the kidney. In each of these tissues, persistent low-grade inflammation is a primary driver of functional decline, and in each of them, SGLT2 inhibitors have shown signals of protection in observational and early interventional data. The convergence is not coincidental. It reflects the deep entanglement between metabolic dysfunction and inflammatory aging that canagliflozin, through its multi-mechanistic profile, appears to partially unwind.

The SGLT2 Protocol at Healthspan is designed precisely to harness these overlapping mechanisms under clinical supervision, pairing canagliflozin's pharmacology with the monitoring and individualization that responsible longevity medicine requires.

Canagliflozin vs. Metformin vs. Rapamycin: Positioning Within the Longevity Pharmacopeia

Positioning canagliflozin within the broader landscape of longevity pharmacology requires an honest comparison with the two most discussed alternatives: metformin and rapamycin. Each has a distinct profile of evidence, mechanism, and risk, and the differences are meaningful for clinical decision-making.

Metformin, like canagliflozin, inhibits mitochondrial Complex I and activates AMPK, and it has a far longer clinical track record, including the TAME (Targeting Aging with Metformin) trial currently underway [14]. Its ITP lifespan data, however, are modest and inconsistent across sexes, and there are legitimate concerns about its potential to blunt exercise-induced adaptations by interfering with mitochondrial stress signaling in skeletal muscle [15]. Canagliflozin's ITP data are more robust, and its cardiovascular outcomes evidence in humans is considerably stronger. For patients interested in the intersection of metabolic and cardiovascular longevity, Metformin may serve a complementary role, but the ITP evidence increasingly favors canagliflozin as the primary SGLT2-class agent.

Rapamycin's ITP data remain the most reproduced and mechanistically understood in mammalian longevity science, with consistent lifespan extensions across multiple cohorts and strong evidence for mTORC1 inhibition as the operative mechanism [3]. The Rapamycin Protocol at Healthspan leverages this evidence base, and rapamycin and canagliflozin are not mutually exclusive. Because they act through largely non-overlapping pathways, with rapamycin primarily inhibiting mTORC1 and canagliflozin primarily operating through AMPK, mitochondrial Complex I inhibition, and glucose-insulin signaling, their combination is theoretically synergistic and is being studied in preclinical models. The ITP has tested the combination of rapamycin with canagliflozin and acarbose, providing some of the most intriguing longevity combination data available [16].

Acarbose, the alpha-glucosidase inhibitor that also has strong ITP data (particularly in males), represents a third node in this emerging longevity pharmacopeia. Like canagliflozin, acarbose reduces postprandial glucose excursions and shifts the metabolic milieu toward relative carbohydrate restriction; it is available through Healthspan's Acarbose program for patients whose metabolic profile makes it appropriate. The mechanistic parallels between acarbose and canagliflozin, both producing relative carbohydrate/glucose substrate limitation, suggest they may share downstream pathways while differing in their primary pharmacological targets.

Because rapamycin and canagliflozin act through largely non-overlapping longevity pathways, their combination is theoretically synergistic, a premise the ITP has begun to test directly in heterogeneous mouse populations.

What sets canagliflozin apart from all three comparators is the combination of robust ITP lifespan data, large-scale human cardiovascular outcomes evidence, and a multi-mechanistic profile that addresses several hallmarks of aging simultaneously. No other single compound in the current longevity pharmacopeia can claim all three. The Canagliflozin program at Healthspan is structured to translate that evidence profile into individualized clinical care, not to deploy a drug indiscriminately but to match its specific mechanistic advantages to the patient's biological risk profile.

The Sex Difference Problem and What It Reveals About Mechanism

One of the most intellectually productive features of the canagliflozin ITP data is the sex difference. Male mice showed a 14% median lifespan extension; female mice showed approximately 7% [1]. This asymmetry is not a failure of the drug in females. It is a biological signal that, interpreted carefully, reveals something important about mechanism.

The ITP researchers identified a likely explanation: female mice show higher blood levels of canagliflozin than males at equivalent doses, because females metabolize the drug more slowly. This means females achieve effective drug exposure at lower doses than males require for the same exposure, and the dose used in the ITP study was designed for male mice, meaning females were functionally overdosed relative to the therapeutic window. When the dose was adjusted for sex differences in pharmacokinetics, the lifespan extension in females improved [1]. The implication for human use is direct: dosing should be individualized, accounting for body composition, metabolic rate, renal function, and sex-related pharmacokinetic differences. This is not a subtle academic point. It is an argument for the kind of precision prescribing that distinguishes a longevity medicine program from a one-size-fits-all pharmacological intervention.

The sex difference also raises questions about hormonal interactions. Estrogen has independent cardioprotective and metabolic effects, and the degree to which endogenous estrogen in female mice attenuates canagliflozin's incremental benefit deserves investigation. In postmenopausal women, where estrogen's protective effects are substantially reduced, SGLT2 inhibitors' cardiovascular and metabolic benefits may be proportionally greater. This is speculative but mechanistically coherent, and it connects the canagliflozin discussion to broader questions about hormone status and metabolic aging that are central to women's longevity medicine.

Canagliflozin in Non-Diabetic Populations: Emerging Evidence and Current Limitations

The critical translational question is whether canagliflozin's longevity mechanisms are relevant to non-diabetic, metabolically healthy individuals, or whether the benefits are largely confined to the correction of pre-existing metabolic dysfunction. The honest answer, as of current evidence, is that the strongest clinical data come from populations with established cardiovascular disease or high metabolic risk. Extrapolation to healthy aging populations is scientifically motivated but not yet directly supported by randomized trial data in non-diabetic cohorts.

Several lines of indirect evidence are encouraging. The ITP mice were healthy and non-diabetic, making the 14% lifespan extension in non-pathological animals the most direct evidence available for longevity effects independent of disease correction [1]. The DAPA-HF trial, which tested a related SGLT2 inhibitor, dapagliflozin, in heart failure patients without diabetes, showed significant reductions in cardiovascular death and worsening heart failure, confirming that at least some benefits are independent of glucose lowering [17]. Mechanistic studies in non-diabetic rodents and cell culture systems confirm that AMPK activation, mitochondrial Complex I inhibition, and anti-inflammatory signaling occur at physiologically relevant drug concentrations regardless of baseline metabolic status [9].

The safety profile in non-diabetic users requires careful consideration. Canagliflozin's most notable adverse effects include an increased risk of genitourinary infections, related to the glucosuria it produces, and a low but real risk of euglycemic diabetic ketoacidosis (DKA), a state of elevated ketones and acidosis occurring without overt hyperglycemia [2]. The DKA risk is substantially lower in non-diabetic individuals with intact insulin secretion, but it is not zero, particularly under conditions of caloric restriction, prolonged fasting, or significant physiological stress. The CANVAS trial also identified a signal for increased fracture risk and a modest increase in lower-limb amputations that has not been consistently replicated in other trials but warrants monitoring [2]. Baseline assessment of renal function is essential, as the drug's efficacy diminishes, and its risks may increase, in the setting of significantly reduced eGFR.

Comprehensive metabolic assessment before and during canagliflozin use is not optional. The Metabolic Pro Panel provides the glucose, insulin, lipid, and renal function data that establish a biological baseline and allow meaningful tracking of treatment response. Longevity pharmacology without baseline diagnostics is, at best, flying blind.

The Gut Microbiome: An Underappreciated Mediator

A growing body of evidence suggests that canagliflozin's effects on the gut microbiome may contribute independently to its metabolic and longevity-relevant benefits. By increasing glucose availability in the intestinal lumen, primarily through reduced renal reabsorption that alters the systemic glucose gradient, and potentially through direct effects on intestinal SGLT1 at higher doses, canagliflozin changes the nutrient environment available to colonic bacteria [18]. The downstream shifts in microbial community composition and metabolite production are not trivial.

Specifically, canagliflozin use has been associated with increased abundance of Akkermansia muciniphila and Lactobacillus species, both associated with improved metabolic health, reduced intestinal permeability, and lower systemic inflammatory tone [18]. Akkermansia in particular has attracted considerable longevity research attention because of its association with reduced inflammation, improved glucose homeostasis, and, in animal models, extended healthspan. The degree to which canagliflozin's cardiovascular and metabolic benefits are mediated through the microbiome is an active area of investigation, and it adds yet another mechanistic layer to an already complex pharmacological profile.

This microbiome dimension also means that canagliflozin's effects are likely to vary based on the individual's pre-existing gut microbial ecology, a source of heterogeneity that partially explains why some patients show more dramatic metabolic responses than others and why dietary context, particularly dietary fiber and fermented food intake, may modulate the drug's efficacy.

Practical Implications for Longevity Medicine

Translating canagliflozin's multi-mechanistic longevity biology into clinical practice requires a framework that is neither dismissive of the preclinical evidence nor uncritical of its limitations. The ITP data, combined with the most robust cardiovascular outcomes evidence in the SGLT2 inhibitor class, justify serious consideration of canagliflozin as a longevity intervention for adults with identifiable metabolic risk factors, early cardiovascular risk, or markers of accelerated biological aging. The evidence does not yet support universal deployment in metabolically healthy young adults, where the risk-benefit calculus is less clear and where behavioral interventions (resistance training, aerobic conditioning, dietary quality, sleep optimization) remain the most evidence-dense longevity tools available.

For middle-aged and older adults with any of the following: elevated fasting insulin, impaired glucose tolerance, early-stage cardiometabolic risk, chronic low-grade inflammation, or evidence of renal hyperfiltration, the mechanistic and clinical case for canagliflozin is substantial. The drug's ability to simultaneously address mitochondrial function, inflammatory tone, cardiovascular hemodynamics, and cellular metabolic signaling through a single, once-daily oral agent is pharmacologically unusual and practically significant. Very few interventions in medicine accomplish this breadth of effect from a single molecule.

The appropriate clinical context is one of informed, supervised use with regular monitoring of renal function, glucose metabolism, and electrolytes. Canagliflozin is not a supplement. It is a prescription medication with a defined mechanism, a meaningful side-effect profile, and interactions with other longevity interventions that require clinical awareness. The Longevity Optimization program at Healthspan provides the comprehensive framework within which canagliflozin can be responsibly incorporated, alongside diagnostics, lifestyle optimization, and the individualized dosing that the ITP sex-difference data make clearly necessary.

A Molecule at the Intersection of Aging's Hallmarks

The reason canagliflozin occupies an increasingly central position in longevity pharmacology is not that it does one thing very well. It is that it does several things, each of which addresses a distinct hallmark of biological aging, with a coherence that suggests the mechanisms are not incidental but convergent. The 2013 Hallmarks of Aging framework identified nine interconnected drivers of biological aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication [19]. An updated 2023 framework expanded this to twelve hallmarks, adding disabled macroautophagy, chronic inflammation, and dysbiosis [20].

Canagliflozin has documented or mechanistically plausible effects on at least six of these twelve hallmarks: deregulated nutrient sensing (via AMPK activation and mTOR suppression), mitochondrial dysfunction (via Complex I modulation and mitophagy promotion), cellular senescence (via SASP suppression), chronic inflammation (via NLRP3 inhibition and NF-kB suppression), dysbiosis (via microbiome remodeling), and disabled macroautophagy (via AMPK-driven autophagy induction). No drug currently in routine clinical use has a documented interaction with this breadth of aging hallmarks from a single mechanism of primary action. That breadth is what makes canagliflozin longevity science genuinely interesting, and what makes the 14% ITP lifespan extension not merely a data point but a biological argument.

Looking Forward: What the Next Decade of Evidence Will Decide

The coming decade will be decisive for canagliflozin as a longevity intervention. Several clinical trials are now examining SGLT2 inhibitors in non-diabetic populations with heart failure, chronic kidney disease, and general cardiovascular prevention, and their results will significantly sharpen the risk-benefit picture in populations closer to the general longevity medicine audience. The EMPEROR-Preserved trial, testing empagliflozin in heart failure with preserved ejection fraction, many of whose patients do not have diabetes, has already shown significant benefit [21], and similar trials for canagliflozin are in progress.

Biomarker studies measuring the effect of canagliflozin on epigenetic aging clocks, a direct measure of biological rather than chronological age, are beginning to appear in the literature and will provide a more granular picture of whether the drug's longevity-relevant mechanisms translate into measurable changes in biological age in living humans. The Longevity Pro Panel, which includes biological aging assessments alongside comprehensive metabolic and cardiovascular biomarkers, represents the kind of monitoring infrastructure that will allow clinicians and patients to generate meaningful individual-level data while the population-level evidence matures.

There is also the combination question. The ITP data on rapamycin plus acarbose plus canagliflozin combinations are preliminary but suggestive of additive effects, consistent with the non-overlapping mechanism hypothesis [16]. If the combination data strengthen with replication, it would support a polypharmacological approach to longevity that treats aging itself, rather than its downstream diseases, as the primary target. That is the direction the field is moving, and canagliflozin is increasingly central to it.

Conclusion: The Most Compelling Case in Longevity Pharmacology

The central question this article opened with was why canagliflozin, a drug designed to make diabetic kidneys leak glucose, might be the most pharmacologically compelling longevity tool in its class. The answer has emerged not from a single finding but from a convergence of evidence streams: the ITP lifespan data placing it alongside rapamycin in magnitude of effect, the cardiovascular outcomes trials providing rare human validation of mechanistic hypotheses, and the basic science revealing a molecule that touches mitochondrial function, inflammatory tone, nutrient sensing, cellular quality control, and microbial ecology through a coherent pharmacological action. The breadth of its mechanistic reach across the hallmarks of aging is, in the current landscape, unmatched by any single drug in routine prescribing.

That does not make it appropriate for everyone, nor does it make it a substitute for the foundational work of sleep, exercise, nutrition, and metabolic monitoring that underpin any serious longevity program. What it does make it is a molecule that demands serious clinical attention from anyone practicing precision longevity medicine. The biology is too coherent, and the human evidence too substantial, to treat canagliflozin as merely an antidiabetic drug that happens to have interesting side effects. It is, in the most precise sense, a drug that addresses aging biology. The scientific community is only beginning to understand what that means.